Brainsway

Advanced Technology Solutions for Brain Disorders

Health Tech & Life Sciences
Public on TASE on Jan, 2007<br>Public on NASDAQ on Apr, 2019<br>

Company Overview

Snapshot

Founded in January 2003 by Avner Hagai, Yiftach Roth, David Zacut, and Abraham Zangen, Brainsway operates with 51–200 employees. The company has raised a total of $79.95M across six funding rounds from six investors. In September 2024, Brainsway announced a US$20 million private placement with Valor Equity Partners.

Business overview

Brainsway develops advanced noninvasive neurostimulation treatments for mental health disorders, leveraging its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology. The company's solutions aim to improve health and transform lives, with current indications including major depressive disorder, obsessive-compulsive disorder (OCD), and smoking addiction. Brainsway serves markets globally, focusing on healthcare providers, hospitals, and clinics, and operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.

Strategic signal

In September 2025, BrainsWay received FDA clearance for an accelerated Deep TMS protocol for the non-invasive treatment of Major Depressive Disorder (MDD). This regulatory approval signals a significant advancement in the company's core technology, potentially broadening patient access and strengthening its market position in mental health treatments by offering a more efficient therapeutic option.

Company Intelligence Q&A

What was a significant recent regulatory achievement for BrainsWay?
In September 2025, BrainsWay received FDA clearance for an accelerated Deep TMS protocol designed for the non-invasive treatment of Major Depressive Disorder (MDD).
What strategic financial move did BrainsWay make in September 2024?
In September 2024, BrainsWay announced a US$20 million private placement with Valor Equity Partners.
What expansion did BrainsWay achieve in East Asia in October 2024?
In October 2024, BrainsWay further penetrated East Asia with the placement of 15 additional Deep TMS™ systems in Taiwan and South Korea, expanding its reach in the region.
What partnership did BrainsWay expand in September 2023 to support U.S. military service members?
In September 2023, BrainsWay broadened access to Deep TMS™ for U.S. military service members through an expanded partnership with Katie’s Way Plus.
What was a notable development regarding PTSD treatment reimbursement in Israel?
In September 2024, the Israel Ministry of Defense cleared BrainsWay Deep TMS™ for PTSD reimbursement at Israeli hospitals.

External links